Envista Holdings Corp (NVST) shareholders
Close on Nov 16, 2026Market cap $3.86BP/E 41.4Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 15,864,543 | 9.20% | 13G (passive) amendment | Mar 31, 2025 |
| Ariel Investments, LLC | 11,359,999 | 6.60% | 13G (passive) | Sep 30, 2024 |
| Dimensional Fund Advisors LP | 9,170,511 | 5.40% | 13G (passive) | Jun 30, 2025 |
| Vanguard Capital Management | 8,574,557 | 5.23% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NVST | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 18,437,542 | 11.48% | $485.83M | +584,715 | 0.01% |
| Ariel Investments, LLC | 9,818,177 | 6.11% | $258.71M | −1,045,415 | 2.58% |
| Dimensional Fund Advisors LP | 9,566,949 | 5.96% | $252.10M | −213,999 | 0.05% |
| Vanguard Portfolio Management LLC | 7,487,670 | 4.66% | $197.30M | −79,051 | 0.01% |
| Vanguard Capital Management LLC | 7,337,916 | 4.57% | $193.35M | +19,335 | 0.00% |
| Morgan Stanley | 6,436,043 | 4.01% | $169.59M | −2,357,094 | 0.01% |
| Gates Capital Management, Inc. | 5,552,383 | 3.46% | $146.31M | +189,672 | 3.52% |
| State Street Corp | 5,329,275 | 3.32% | $140.49M | +100,517 | 0.00% |
| Alliancebernstein L.P. | 5,213,644 | 3.25% | $132.27M | +185,033 | 0.04% |
| Arrowstreet Capital, Limited Partnership | 4,847,940 | 3.02% | $127.74M | +1,989,647 | 0.06% |
| Franklin Resources Inc | 4,810,040 | 2.99% | $126.74M | −2,083,985 | 0.03% |
| Victory Capital Management Inc | 4,494,346 | 2.80% | $118.43M | +101,278 | 0.07% |
| Ilex Capital Partners (UK) LLP | 4,372,709 | 2.72% | $115.22M | New | 2.36% |
| Quantinno Capital Management LP | 4,194,886 | 2.61% | $110.54M | +1,499,916 | 0.13% |
| Aqr Capital Management LLC | 4,023,691 | 2.51% | $106.02M | +1,405,574 | 0.04% |
| Neuberger Berman Group LLC | 3,876,747 | 2.41% | $102.15M | +3,864,108 | 0.07% |
| Fuller & Thaler Asset Management, Inc. | 3,642,097 | 2.27% | $95.97M | −131,655 | 0.26% |
| JPMorgan Chase & Co | 3,304,946 | 2.06% | $89.50M | +388,702 | 0.00% |
| Geode Capital Management, LLC | 3,150,508 | 1.96% | $83.04M | +1,213 | 0.00% |
| American Century Companies Inc | 3,052,519 | 1.90% | $80.43M | −149,107 | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 382 | 190M | 100.0% | 51 / 147 | 130 / 56 | 33M | 21M |
| Q1 2026 | 392 | 178M | 100.0% | 95 / 130 | 120 / 32 | 37M | 28M |
| Q4 2025 | 337 | 186M | 100.0% | 65 / 116 | 114 / 37 | 21M | 26M |
| Q3 2025 | 312 | 191M | 100.0% | 59 / 105 | 103 / 28 | 14M | 23M |
| Q2 2025 | 285 | 200M | 100.0% | 45 / 92 | 119 / 47 | 20M | 15M |
| Q1 2025 | 289 | 195M | 100.0% | 44 / 115 | 89 / 41 | 23M | 23M |
| Q4 2024 | 291 | 195M | 100.0% | 39 / 88 | 122 / 42 | 20M | 23M |
| Q3 2024 | 298 | 198M | 100.0% | 53 / 104 | 106 / 46 | 42M | 19M |
| Q2 2024 | 292 | 194M | 100.0% | 29 / 136 | 100 / 38 | 30M | 58M |
| Q1 2024 | 302 | 223M | 100.0% | 41 / 119 | 115 / 57 | 46M | 27M |
| Q4 2023 | 319 | 204M | 100.0% | 77 / 144 | 71 / 69 | 60M | 31M |
| Q3 2023 | 316 | 176M | 100.0% | 43 / 116 | 124 / 45 | 15M | 21M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
401 funds held NVST in Q2 2026, 37% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NVST | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 5,573,255 | 3.47% | $146.86M | 0.12% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 5,158,976 | 3.21% | $135.94M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,733,859 | 2.32% | $98.39M | 0.05% | Jun 30, 2026 |
| Eaton Vance Atlanta Capital SMID-Cap Fund | 3,389,824 | 2.11% | $89.32M | 1.02% | Jun 30, 2026 |
| Ariel Fund | 3,384,359 | 2.11% | $89.18M | 3.08% | Jun 30, 2026 |
| Undiscovered Managers Behavioral Value Fund | 2,983,701 | 1.86% | $78.62M | 0.87% | Jun 30, 2026 |
| Franklin Small Cap Value Fund | 2,570,956 | 1.60% | $70.21M | 1.64% | Jul 31, 2026 |
| Vanguard Small-Cap Value Index Fund | 2,364,068 | 1.47% | $62.29M | 0.09% | Jun 30, 2026 |
| U.S. Small Cap Value Portfolio | 2,235,061 | 1.39% | $61.04M | 0.31% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,865,888 | 1.16% | $49.17M | 0.05% | Jun 30, 2026 |
| BlackRock Event Driven Equity Fund | 1,728,308 | 1.08% | $40.70M | 0.85% | May 29, 2026 |
| Mid Cap Value Fund | 1,574,304 | 0.98% | $41.48M | 0.73% | Jun 30, 2026 |
| JPMorgan Small Cap Equity Fund | 1,520,560 | 0.95% | $40.07M | 1.39% | Jun 30, 2026 |
| Victory Sycamore Small Company Opportunity Fund | 1,500,000 | 0.93% | $39.53M | 0.84% | Jun 30, 2026 |
| MFS Blended Research Mid Cap Equity Fund | 1,333,961 | 0.83% | $31.41M | 1.07% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul A. Keel | Chairman and CEO, Director | 497,107 | 0.31% | Nov 2, 2026 |
| Robert Befidi | President, Diagnostics | 45,785 | 0.03% | Aug 27, 2026 |
| Veronica Acurio | President, Orthodontics | 48,806 | 0.03% | Aug 27, 2026 |
| Eric D. Hammes | Chief Financial Officer | 99,913 | 0.06% | Aug 27, 2026 |
| Stefan Nilsson | President, Nobel Biocare | 61,560 | 0.04% | Aug 27, 2026 |
| Mischa Reis | SVP, Strategy & Bus. Dev. | 27,321 | 0.02% | Aug 24, 2026 |
| Coree K. Thomas | CAO | 2,535 | 0.00% | Aug 13, 2026 |
| Faez C. Kaabi | Chief Accounting Officer | 58,552 | 0.04% | Feb 27, 2026 |
| Mark E. Nance | General Counsel | 68,577 | 0.04% | Feb 27, 2026 |
| Daniel Raskas | Director | 54,010 | 0.03% | May 21, 2026 |
| Christine A. Tsingos | Director | 59,930 | 0.04% | May 21, 2026 |
| Vivek Jain | Director | 52,945 | 0.03% | May 21, 2026 |
| Wendy Carruthers | Director | 59,940 | 0.04% | May 21, 2026 |
| R. Scott Huennekens | Director | 82,105 | 0.05% | May 21, 2026 |
| Kieran Gallahue | Director | 54,010 | 0.03% | May 21, 2026 |
| James Andrew Pierce | Director | 18,485 | 0.01% | May 21, 2026 |
| Barbara B. Hulit | Director | 79,820 | 0.05% | Jun 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Paul A. Keel Chairman and CEO, Director | Nov 1, 2026 | Tax withholding | −54,197 | $23.51 | $1.27M | 497,107 |
| Stefan Nilsson President, Nobel Biocare | Aug 25, 2026 | Tax withholding | −804 | $27.47 | $22.09K | 61,560 |
| Veronica Acurio President, Orthodontics | Aug 25, 2026 | Tax withholding | −7,710 | $27.47 | $211.79K | 48,806 |
| Robert Befidi President, Diagnostics | Aug 25, 2026 | Tax withholding | −5,147 | $27.47 | $141.39K | 45,785 |
| Eric D. Hammes Chief Financial Officer | Aug 25, 2026 | Tax withholding | −10,885 | $27.47 | $299.01K | 99,913 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Aug 20, 2026 | Sale(10b5-1 plan) | −8,000 | $27.50 | $220.00K | 27,321 |
| Paul A. Keel Chief Executive Officer, Director | Aug 18, 2026 | Award | +179,730 | – | – | 551,304 |
| Paul A. Keel Chief Executive Officer, Director | May 25, 2026 | Tax withholding | −12,811 | $23.43 | $300.16K | 371,574 |
| Vivek Jain Director | May 19, 2026 | Award | +9,330 | – | – | 52,945 |
| R. Scott Huennekens Director | May 19, 2026 | Award | +12,585 | – | – | 82,105 |
| James Andrew Pierce Director | May 19, 2026 | Award | +9,330 | – | – | 18,485 |
| Kieran Gallahue Director | May 19, 2026 | Award | +9,330 | – | – | 54,010 |
| Wendy Carruthers Director | May 19, 2026 | Award | +9,330 | – | – | 59,940 |
| Daniel Raskas Director | May 19, 2026 | Award | +9,330 | – | – | 54,010 |
| Christine A. Tsingos Director | May 19, 2026 | Award | +9,330 | – | – | 59,930 |
| Faez C. Kaabi Chief Accounting Officer | Feb 25, 2026 | Award | +13,520 | – | – | 58,552 |
| Faez C. Kaabi Chief Accounting Officer | Feb 25, 2026 | Tax withholding | −4,964 | $29.59 | $146.88K | 45,032 |
| Eric D. Hammes Chief Financial Officer | Feb 25, 2026 | Award | +16,055 | – | – | 110,798 |
| Eric D. Hammes Chief Financial Officer | Feb 25, 2026 | Tax withholding | −2,045 | $29.59 | $60.51K | 94,743 |
| Veronica Acurio President, Orthodontics | Feb 25, 2026 | Award | +7,605 | – | – | 56,516 |
| Veronica Acurio President, Orthodontics | Feb 25, 2026 | Tax withholding | −1,412 | $29.59 | $41.78K | 48,911 |
| Mark E. Nance General Counsel | Feb 25, 2026 | Tax withholding | −3,368 | $29.59 | $99.66K | 68,577 |
| Mark E. Nance General Counsel | Feb 25, 2026 | Award | +12,675 | – | – | 81,252 |
| Robert Befidi President, Diagnostics | Feb 25, 2026 | Award | +7,605 | – | – | 50,932 |
| Robert Befidi President, Diagnostics | Feb 25, 2026 | Tax withholding | −2,177 | $29.59 | $64.42K | 43,327 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 25, 2026 | Award | +5,915 | – | – | 35,321 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 25, 2026 | Tax withholding | −2,976 | $29.59 | $88.06K | 29,406 |
| Stefan Nilsson President, Nobel Biocare | Feb 25, 2026 | Award | +7,605 | – | – | 62,364 |
| Stefan Nilsson President, Nobel Biocare | Feb 25, 2026 | Tax withholding | −182 | $29.59 | $5.39K | 54,759 |
| Paul A. Keel Chief Executive Officer, Director | Feb 25, 2026 | Tax withholding | −11,840 | $29.59 | $350.35K | 335,715 |
| Paul A. Keel Chief Executive Officer, Director | Feb 25, 2026 | Award | +48,670 | – | – | 384,385 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 10, 2026 | Option exercise | +5,634 | $15.97 | $89.97K | 38,016 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 10, 2026 | Option exercise | +4,041 | $19.04 | $76.94K | 36,423 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 10, 2026 | Sale(10b5-1 plan) | −4,041 | $30.00 | $121.23K | 32,382 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 10, 2026 | Sale(10b5-1 plan) | −5,634 | $30.00 | $169.02K | 32,382 |
| Paul A. Keel Chief Executive Officer, Director | Nov 1, 2025 | Tax withholding | −54,097 | $20.35 | $1.10M | 347,555 |
| Eric D. Hammes Chief Financial Officer | Aug 25, 2025 | Tax withholding | −7,654 | $21.12 | $161.65K | 96,788 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Aug 25, 2025 | Sale(10b5-1 plan) | −15,000 | $21.60 | $324.00K | 32,382 |
| Robert Befidi President, Diagnostics | Aug 25, 2025 | Tax withholding | −3,454 | $21.12 | $72.95K | 45,504 |
| Veronica Acurio President, Orthodontics | Aug 25, 2025 | Tax withholding | −5,422 | $21.12 | $114.51K | 50,323 |
| Stefan Nilsson President, Nobel Biocare | Aug 25, 2025 | Tax withholding | −804 | $21.12 | $16.98K | 54,941 |
| James Andrew Pierce Director | Jul 14, 2025 | Award | +9,155 | – | – | 9,155 |
| Wendy Carruthers Director | Jun 10, 2025 | Award | +10,450 | – | – | 50,610 |
| Daniel Raskas Director | Jun 10, 2025 | Award | +10,450 | – | – | 44,680 |
| Christine A. Tsingos Director | Jun 10, 2025 | Award | +10,450 | – | – | 50,600 |
| Vivek Jain Director | Jun 10, 2025 | Award | +10,450 | – | – | 43,615 |
| R. Scott Huennekens Director | Jun 10, 2025 | Award | +14,370 | – | – | 69,520 |
| Kieran Gallahue Director | Jun 10, 2025 | Award | +10,450 | – | – | 44,680 |
| Barbara B. Hulit Director | Jun 10, 2025 | Award | +10,450 | – | – | 79,820 |
| Paul A. Keel Chief Executive Officer, Director | May 25, 2025 | Tax withholding | −12,787 | $16.72 | $213.80K | 401,652 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 26, 2025 | Award | +8,475 | – | – | 47,382 |
| Robert Befidi President, Diagnostics | Feb 25, 2025 | Award | +10,290 | – | – | 48,958 |
| Robert Befidi President, Diagnostics | Feb 25, 2025 | Tax withholding | −1,123 | $20.66 | $23.20K | 38,668 |
| Veronica Acurio President, Orthodontics | Feb 25, 2025 | Award | +10,290 | – | – | 55,745 |
| Stefan Nilsson President, Nobel Biocare | Feb 25, 2025 | Award | +10,290 | – | – | 55,745 |
| Eric D. Hammes Chief Financial Officer | Feb 25, 2025 | Award | +15,735 | – | – | 104,442 |
| Paul A. Keel Chief Executive Officer, Director | Feb 25, 2025 | Award | +65,830 | – | – | 414,439 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 25, 2025 | Tax withholding | −3,813 | $20.66 | $78.78K | 38,907 |
| Faez C. Kaabi Chief Accounting Officer | Feb 25, 2025 | Tax withholding | −4,319 | $20.66 | $89.23K | 40,311 |
| Faez C. Kaabi Chief Accounting Officer | Feb 25, 2025 | Award | +9,685 | – | – | 49,996 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Envista's stock actually held short. Settlement fails (shares not delivered on time) peaked at 37,946 shares on Aug 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mischa Reis Officer | Aug 20, 2026 | 8,000 | $220.00K | Aug 20, 2026 | Restricted Stock Vesting |
| Mischa Reis Officer | Feb 10, 2026 | 9,675 | $290.25K | Feb 10, 2026 | Options Granted - 05/15/2017 |
| Mischa Reis Officer | Aug 25, 2025 | 15,000 | $324.00K | Aug 25, 2025 | Restricted Stock Vesting |
| Eric Conley Former Officer | Aug 6, 2024 | 12,798 | $204.83K | Aug 6, 2024 | Restricted Stock Vesting |
| Eric Conley Former Officer | Jun 21, 2024 | 9,185 | $158.65K | Jun 21, 2024 | Open Market Purchase |
| Yu Howard H Former Officer | Oct 5, 2023 | 3,717 | $104.11K | Oct 5, 2023 | Restricted Stock Vesting |
| Yu Howard H Former Officer | Oct 4, 2023 | 60,531 | $1.63M | Oct 4, 2023 | Option Granted - 02/24/2017 |
See a number that looks wrong?